A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study

Journal of Dental Research

Volumn 94, Issue , 2015, Pages 212S-219S

  Kwon, J W ^a   Park, E J ^b   Jung, S Y ^c   Sohn, H S ^d   Ryu, H ^a   Suh, H S ^e  

^a Kyungpook National University   (South Korea)

^b Korea Inst Hlth and Social Aff   (South Korea)

^c Korea Institute of Drug Safety and Risk Management   (South Korea)

^d CHA University   (South Korea)

^e Pusan National University   (South Korea)

Author keywords

Asian Continental Ancestry Group; bisphosphonate associated osteonecrosis of the jaw; drug related side effects and adverse reactions; Korea epidemiology; medication compliance; retrospective studies

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

ADOLESCENT; ADULT; AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; HEALTH SURVEY; HUMAN; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; POPULATION SURVEILLANCE; RISK FACTORS; YOUNG ADULT;

EID: 84939796244     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034515587862     Document Type: Article

References (32)

1. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R,. 2006. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 24 (6): 945-952.
2. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C,. 2005. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 23 (34): 8580-8587.
3. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE, CONDOR Collaborative Group. 2011. Risk factors for osteonecrosis of the jaws a case-control study from the CONDOR Dental PBRN. J Dent Res. 90 (4): 439-444.
4. Bergdahl J, Jarnbring F, Ehrenstein V, Gammelager H, Granath F, Kieler H, Svensson M, Tell GS, Lagerros YT,. 2013. Evaluation of an algorithm ascertaining cases of osteonecrosis of the jaw in the Swedish National Patient Register. Clin Epidemiol. 5: 1-7.
5. Cooper C, Steinbuch M, Stevenson R, Miday R, Watts N,. 2010. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporosis Int. 21 (4): 569-577.
6. Cramer JA, Gold DT, Silverman SL, Lewiecki EM,. 2007. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int. 18 (8): 1023-1031.
7. Drake MT, Clarke BL, Khosla S,. 2008. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 83 (9): 1032-1045.
8. Etminan M, Aminzadeh K, Matthew IR, Brophy JM,. 2008. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol. 35 (4): 691-695.
9. Gu XS, Rosenbaum PR,. 1993. Comparison of multivariate matching methods: structures, distances, and algorithms. J Comput Graph Stat. 2 (4): 405-420.
10. Harvey N, Dennison E, Cooper C,. 2010. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. 6 (2): 99-105.
11. Hong J, Nam W, Cha IH, Chung SW, Choi H, Kim K, Kim K, Rhee Y, Lim SK,. 2010. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporosis Int. 21 (5): 847-853.
12. International Osteoporosis Foundation. 2009. The Asian audit: epidemiology, costs and burden of osteoporosis in Asia 2009. Nyon (Switzerland): International Osteoporosis Foundation.
13. Jang S, Park C, Jang S, Yoon HK, Shin CS, Kim DY, Ha YC, Lee SS, Choi HJ, Lee YK,. 2010. Medical service utilization with osteoporosis. Endocrinol Metab. 25 (4): 326-339.
14. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S,. 2007. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 22 (10): 1479-1491.
15. Lapi F, Cipriani F, Caputi A, Corrao G, Vaccheri A, Sturkenboom M, Di Bari M, Gregori D, Carle F, Staniscia T,. 2013. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. Osteoporosis Int. 24 (2): 697-705.
16. Lee JY, Kim KH, Lee JS,. 2014. Establishment of a nation cohort sample database using national health insurance data. Seoul (Korea): National Health Insurance Service.
17. Lee SH, Chang SS, Lee M, Chan RC, Lee CC,. 2014. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis. Osteoporosis Int. 25 (3): 1131-1139.
18. Lee YK, Yoon BH, Koo KH,. 2013. Epidemiology of osteoporosis and osteoporotic fractures in South Korea. Endocrinol Metab (Seoul). 28 (2): 90-93.
19. Lim S, Koo BK, Lee EJ, Park JH, Kim MH, Shin KH, Ha YC, Cho NH, Shin CS,. 2008. Incidence of hip fractures in Korea. J Bone Miner Metab. 26 (4): 400-405.
20. Marx RE,. 2003. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxil Surg. 61 (9): 1115-1117.
21. Marx RE, Sawatari Y, Fortin M, Broumand V,. 2005. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 63 (11): 1567-1575.
22. Mayo Clinic. 2014. Diseases and conditions: osteoporosis. Risk factors: unchangeable risks. [. accessed 2015 Apr 28 ]. http://www.mayoclinic.org/diseases-conditions/osteoporosis/basics/risk-factors/con-20019924.
23. Park C, Ha YC, Jang S, Jang S, Yoon HK, Lee YK,. 2011. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 29 (6): 744-751.
24. Park W, Kim N-K, Kim M-Y, Rhee Y-M, Kim H,. 2010. Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporosis Int. 21 (3): 527-533.
25. Pazianas M, Blumentals W, Miller P,. 2008. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporosis Int. 19 (6): 773-779.
26. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P,. 2007. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 29 (8): 1548-1558.
27. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA,. 2005. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 43 (11): 1130-1139.
28. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S,. 2006. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81 (8): 1013-1022.
29. Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS,. 2012. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 21 (8): 810-817.
30. Watts NB, Diab DL,. 2010. Long-term use of bisphosphonates in osteoporosis. J Clin Endocr Metab. 95 (4): 1555-1565.
31. Woo S-B, Hellstein JW, Kalmar JR,. 2006. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 144 (10): 753-761.
32. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, Nakayama T, Bessho K,. 2012. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Max Surg. 41 (11): 1397-1403.